EASME – ENYO helps your body give the cold shoulder to viruses
https://ec.europa.eu/easme/en/news/enyo-helps-your-body-give-cold-shoulder-viruses
ENYO Pharma SA announces successful completion of EYP001 first in man Phase 1 study
Lyon, June 14, 2017 – ENYO Pharma SA, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1a single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been completed. The results show that EYP001 was safe and well-tolerated at all doses studied in 80 subjects. The safety, pharmacokinetics (PK) and pharmacodynamic (PD) analysis are in line with established FXR biology and reported results from other early stage compounds that are in development for NASH.
ENYO Pharma strengthens its business team to support International growth
Lyon, the 10th of May 2017. ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, has today announced that it is strengthening its business team with the appointment of a CFO and a VP Corporate Development and Strategy, both individuals having strong experience in the pharmaceutical businesses.
MIMESIS Newsletter #1: a novel systems biology approach to develop preclinical assets
MIMESIS NEWSLETTER #1, April 2017
A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.
Latest Press Release 